Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪9.91 B‬EUR
−1.48EUR
‪−438.45 M‬EUR
‪681.15 M‬EUR
‪158.19 M‬
Beta (1Y)
1.06
Employees (FY)
‪1.07 K‬
Change (1Y)
+142 +15.32%
Revenue / Employee (1Y)
Net income / Employee (1Y)

About Ionis Pharmaceuticals, Inc.


CEO
Brett P. Monia
Website
Headquarters
Carlsbad
Founded
1989
ISIN
US4622221004
FIGI
BBG000FHW679
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Check out other big names from the same industry as ISI.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
VTI
Vanguard Total Stock Market ETF
Weight
0.02%
Market value
‪312.72 M‬
USD
VB
Vanguard Small-Cap ETF
Weight
0.14%
Market value
‪234.79 M‬
USD
VBK
Vanguard Small-Cap Growth ETF
Weight
0.33%
Market value
‪131.35 M‬
USD
XBI
SPDR S&P BIOTECH ETF
Weight
1.90%
Market value
‪128.14 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.13%
Market value
‪111.62 M‬
USD
IWP
iShares Russell Mid-Cap Growth ETF
Weight
0.34%
Market value
‪71.14 M‬
USD
IBB
iShares Biotechnology ETF
Weight
1.08%
Market value
‪70.51 M‬
USD
SCHA
Schwab U.S. Small-Cap ETF
Weight
0.29%
Market value
‪55.66 M‬
USD
ARKG
ARK Genomic Revolution ETF
Weight
3.50%
Market value
‪46.39 M‬
USD
IWF
iShares Russell 1000 Growth ETF
Weight
0.03%
Market value
‪41.01 M‬
USD
IWR
iShares Russell Midcap ETF
Weight
0.09%
Market value
‪40.88 M‬
USD

Explore more ETFs 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Ionis Pharmaceuticals, Inc. stocks are traded under the ticker ISI.
We've gathered analysts' opinions on Ionis Pharmaceuticals, Inc. future price: according to them, ISI price has a max estimate of 82.16 EUR and a min estimate of 39.37 EUR. Watch ISI chart and read a more detailed Ionis Pharmaceuticals, Inc. stock forecast: see what analysts think of Ionis Pharmaceuticals, Inc. and suggest that you do with its stocks.
ISI reached its all-time high on Apr 9, 2019 with the price of 76.06 EUR, and its all-time low was 2.16 EUR and was reached on May 5, 2005. View more price dynamics on ISI chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Ionis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Ionis Pharmaceuticals, Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
ISI earnings for the last quarter are 0.59 EUR per share, whereas the estimation was −0.08 EUR resulting in a 868.38% surprise. The estimated earnings for the next quarter are −1.04 EUR per share. See more details about Ionis Pharmaceuticals, Inc. earnings.
Ionis Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪383.70 M‬ EUR, despite the estimated figure of ‪253.23 M‬ EUR. In the next quarter, revenue is expected to reach ‪111.44 M‬ EUR.
ISI net income for the last quarter is ‪104.88 M‬ EUR, while the quarter before that showed ‪−135.82 M‬ EUR of net income which accounts for 177.22% change. Track more Ionis Pharmaceuticals, Inc. financial stats to get the full picture.
No, ISI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 17, 2025, the company has ‪1.07 K‬ employees. See our rating of the largest employees — is Ionis Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ionis Pharmaceuticals, Inc. EBITDA is ‪−207.21 M‬ EUR, and current EBITDA margin is −64.26%. See more stats in Ionis Pharmaceuticals, Inc. financial statements.
Like other stocks, ISI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ionis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.